In the UK, T-DXd is currently licenced as monotherapy for the treatment of patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens [6] and its use for the same FDA approved indication is being considered by the National Institute for Health and Care Excellence (NICE). Here, ERBB2 is linked to breast carcinoma.